Douglas B. Johnson, MD, MSCI

Professor of Medicine of Hematology/Oncology
777 PRB
Nashville
Tennessee

Biomarkers for immune and targeted therapeutics; Developing clinical trials for melanoma patients

Douglas Johnson, MD, MSCI, received his MD from the University of Alabama School of Medicine and completed his internal medicine residency at Duke University before coming to Vanderbilt for a hematology/oncology fellowship. He has been on faculty at Vanderbilt since 2014 and is a Professor of Medicine.

Within Vanderbilt-Ingram Cancer Center, he serves as Director of the Melanoma and Vanderbilt Precision Oncology Programs, Principal Investigator of the Vanderbilt Oncology Training Program T32, and Associate Director for Translational Research. He holds the Susan and Luke Simons Endowed Directorship.

Research Information

Dr. Johnson leads the melanoma clinical research program at Vanderbilt. His research interests cover a wide range of developing new immune and targeted therapies for melanoma, and in using existing treatments in the most effective ways. Specifically, he is exploring ways to profile cancers to predict which patients will benefit from immune therapies, and has published numerous papers in this area. He is also focused on understanding the effectiveness and toxicities of immune therapies in high risk patients, including those with autoimmune disorders, advanced age, or organ dysfunction. Dr. Johnson is the lead investigator on numerous clinical trials at Vanderbilt.

Publications on PubMed.gov